Monte Rosa Therapeutics, Inc. Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities
Monte Rosa Therapeutics, Inc. (GLUE) reported Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities of -$1.50 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities · last filed 2026-08-06
- Monte Rosa Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-06-30 was $2.21M.
- Monte Rosa Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2026-03-31 was -$3.71M.
- Monte Rosa Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-12-31 was $8.73M, a 136.27% increase year-over-year.
- Monte Rosa Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for the quarter ending 2025-09-30 was $4.19M, a 80.08% increase year-over-year.
- Monte Rosa Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2025 was $7.85M, a 87.67% increase from fiscal 2024.
- Monte Rosa Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2024 was $4.18M, a 17.63% increase from fiscal 2023.
- Monte Rosa Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2023 was $3.56M, a 245.00% increase from fiscal 2022.
- Monte Rosa Therapeutics, Inc. increase (decrease) in accrued liabilities and other operating liabilities for fiscal 2022 was $1.03M, a 84.35% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 3 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 6 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 9 month | Increase (Decrease) in Accrued Liabilities and Other Operating Liabilities 12 month |
|---|---|---|---|---|
| 2026-06-30 | $2.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$1.50M 10-Q · filed 2026-08-06 | $7.23M derived: sum of 3 quarters · filed 2026-08-06 | $11.43M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | -$3.71M 10-Q · filed 2026-05-07 | $5.02M derived: sum of 2 quarters · filed 2026-05-07 | $9.22M derived: sum of 3 quarters · filed 2026-05-07 | $6.75M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $8.73M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $12.93M derived: sum of 2 quarters · filed 2026-03-17 | $10.46M derived: sum of 3 quarters · filed 2026-08-06 | $7.85M 10-K · filed 2026-03-17 |
| 2025-09-30 | $4.19M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.72M derived: sum of 2 quarters · filed 2026-08-06 | -$883.00K 10-Q · filed 2025-11-06 | $2.81M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | -$2.47M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | -$5.08M 10-Q · filed 2026-08-06 | -$1.38M derived: sum of 3 quarters · filed 2026-08-06 | $949.00K derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | -$2.61M 10-Q · filed 2026-05-07 | $1.09M derived: sum of 2 quarters · filed 2026-05-07 | $3.42M derived: sum of 3 quarters · filed 2026-05-07 | $5.46M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $3.70M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-17 | $6.03M derived: sum of 2 quarters · filed 2026-03-17 | $8.07M derived: sum of 3 quarters · filed 2026-03-17 | $4.18M 10-K · filed 2026-03-17 |
| 2024-09-30 | $2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $4.37M derived: sum of 2 quarters · filed 2025-11-06 | $487.00K 10-Q · filed 2025-11-06 | $1.78M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $2.04M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | -$1.84M 10-Q · filed 2025-08-07 | -$553.00K derived: sum of 3 quarters · filed 2025-08-07 | $2.23M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | -$3.89M 10-Q · filed 2025-05-08 | -$2.60M derived: sum of 2 quarters · filed 2025-05-08 | $191.00K derived: sum of 3 quarters · filed 2025-05-08 | $2.96M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $1.29M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-20 | $4.08M derived: sum of 2 quarters · filed 2025-03-20 | $6.84M derived: sum of 3 quarters · filed 2025-03-20 | $3.56M 10-K · filed 2025-03-20 |
| 2023-09-30 | $2.79M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | $5.55M derived: sum of 2 quarters · filed 2024-11-07 | $2.27M 10-Q · filed 2024-11-07 | $4.34M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $2.77M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | -$520.00K 10-Q · filed 2024-08-08 | $1.55M derived: sum of 3 quarters · filed 2024-08-08 | $2.71M derived: sum of 4 quarters · filed 2024-08-08 |
| 2023-03-31 | -$3.29M 10-Q · filed 2024-05-09 | -$1.21M derived: sum of 2 quarters · filed 2024-05-09 | -$58.00K derived: sum of 3 quarters · filed 2024-05-09 | $1.30M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $2.07M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-14 | $3.23M derived: sum of 2 quarters · filed 2024-03-14 | $4.59M derived: sum of 3 quarters · filed 2024-03-14 | $1.03M 10-K · filed 2024-03-14 |
| 2022-09-30 | $1.16M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | $2.52M derived: sum of 2 quarters · filed 2023-11-09 | -$1.04M 10-Q · filed 2023-11-09 | -$1.18M derived: sum of 4 quarters · filed 2023-11-09 |
| 2022-06-30 | $1.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | -$2.20M 10-Q · filed 2023-08-10 | -$2.33M derived: sum of 3 quarters · filed 2023-08-10 | $3.55M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | -$3.56M 10-Q · filed 2023-05-11 | -$3.70M derived: sum of 2 quarters · filed 2023-05-11 | $2.18M derived: sum of 3 quarters · filed 2023-05-11 | $3.77M derived: sum of 4 quarters · filed 2023-05-11 |
| 2021-12-31 | -$139.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-16 | $5.74M derived: sum of 2 quarters · filed 2023-03-16 | $7.33M derived: sum of 3 quarters · filed 2023-03-16 | $6.59M 10-K · filed 2023-03-16 |
| 2021-09-30 | $5.88M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-10 | $7.46M derived: sum of 2 quarters · filed 2022-11-10 | $6.73M 10-Q · filed 2022-11-10 | $7.41M derived: sum of 4 quarters · filed 2022-11-10 |
| 2021-06-30 | $1.58M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | $844.00K 10-Q · filed 2022-08-11 | $1.53M derived: sum of 3 quarters · filed 2022-08-11 | $1.78M derived: sum of 4 quarters · filed 2022-08-11 |
| 2021-03-31 | -$738.00K 10-Q · filed 2022-05-11 | -$55.00K derived: sum of 2 quarters · filed 2022-05-11 | $201.00K derived: sum of 3 quarters · filed 2022-05-11 | |
| 2020-12-31 | $683.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-29 | $939.00K derived: sum of 2 quarters · filed 2022-03-29 | $1.13M 10-K · filed 2022-03-29 | |
| 2020-09-30 | $256.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $447.00K 10-Q · filed 2021-11-10 | ||
| 2020-06-30 | $191.00K 10-Q · filed 2021-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cullinan Therapeutics, Inc. (CGEM) | United States | $0.993B | -5.72 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |